Ariceum Therapeutics
Brigitta Voss serves as the Head of Program and Portfolio Management at Ariceum Therapeutics since August 2023 and is also a Lecturer in Project Management at aprentas since January 2023. With extensive experience, Brigitta has been a Judge, Expert, and Mentor at MassChallenge Switzerland since March 2020. Previously, Brigitta held the position of SVP Portfolio and Project Management at Hookipa Pharma Inc. from September 2019 to March 2020 and served various roles at Hoffmann-La Roche from January 2009 to August 2019, including Head of Biologics Portfolio Management and Innovation Portfolio Leader. Brigitta's career began as a Project Manager at Novartis from October 2006 to December 2008. Educational qualifications include an Executive MBA from IMD (2018-2019), an ECPM from the University of Basel (2007-2009), and a PhD in Statistics from TU Dortmund University (1997-2003), where Brigitta also earned a Master's degree in Statistics (1989-1997).
This person is not in any teams
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.